Published: 13 Dec, 2018 | Tags: Novartis, Xolair, (omalizumab), Receives, EU, Approval, Severe Allergic Asthma, (SAA), Chronic Spontaneous Urticaria (CSU)

2.   Axovant Sciences Licenses Two Gene Therapy Programs from University of Massachusetts for Rare and Fatal Neurodegenerative Genetic Disorders

Published: 13 Dec, 2018 | Tags: Axovant Sciences, Licenses, Two, Gene Therapy, Programs, University of Massachusetts, Rare, Fatal, Neurodegenerative Genetic Disorders

3.   Vertex‘s Orkambi (lumacaftor/ivacaftor) Receives Health Canada Approval for Cystic Fibrosis (CF) Aged 2 to 5 yrs.

Published: 13 Dec, 2018 | Tags: Vertex, Orkambi, (lumacaftor/ivacaftor) ,Receives ,Health Canada, Approval, Cystic Fibrosis, (CF) ,Aged, 2yrs, 5 yrs, EMA, the US FDA

4.   Eli Lilly’s Olumiant (baricitinib) Receives FDA’s Fast Track Designation for Systemic Lupus Erythematosus (SLE)

Published: 13 Dec, 2018 | Tags: Eli Lilly, Olumiant, (baricitinib), Receives, FDA, Fast Track Designation, Systemic Lupus Erythematosus, (SLE)

5.   Lilly Collaborates with AC Immune (AC) to Develop Candidates for Neurodegenerative Diseases

Published: 12 Dec, 2018 | Tags: Lilly, Collaborates, AC Immune, Develop, Candidates, Alzheimer Disease, Neurodegenerative Diseases

6.   AstraZeneca and AVEO Oncology Enters into an Immuno-Oncology Clinical Collaboration     

Published: 12 Dec, 2018 | Tags: AstraZeneca, AVEO Oncology, Enters, Immuno-Oncology, Clinical Collaboration

7.   Merck Collaborates with Instituto Butantan to Develop Vaccines for Dengue

Published: 11 Dec, 2018 | Tags: Merck, Collaborates, Instituto Butantan, Develop , Vaccines, Dengue Infection, TV003

8.   Oxford BioTherapeutics Licenses WuXi Biologics’ WuXiBody Platform for the Development of Five Bispecific Antibodies

Published: 11 Dec, 2018 | Tags: Oxford BioTherapeutics, Licenses, WuXi Biologics, WuXiBody Platform, Five Bispecific Antibodies

9.   Circassia Plans to Exercise Option for the US Commercialization Rights for Tudorza (aclidinium) From AstraZeneca

Published: 11 Dec, 2018 | Tags: Circassia, Plans, Exercise, Option, the US, Commercialization, Rights, Tudorza, (aclidinium), AstraZeneca

10. Astellas to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3 Mutation, in the US

Published: 11 Dec, 2018 | Tags: Astellas, Launch, Xospata, (gilteritinib), R/R Acute Myeloid Leukemia, (AML), FLT3 Mutation, the US

11. Sandoz Receives FDA’s Clearance for reSET-O, a Medical Mobile App for Opioid Use Disorder (OUD)

Published: 10 Dec, 2018 | Tags: Sandoz, Receives, FDA, Clearance, reSET-O, Medical, Mobile App, Opioid Use Disorder (OUD)

12. Shionogi Signs a Research Collaboration with UBE Industries for the Development of Anti-RS Virus Drug Candidates

Published: 10 Dec, 2018 | Tags: Shionogi, Signs, Research, Collaboration, UBE Industries, Development, Anti-RS Virus Drug Candidates

13. Novartis Reports Results of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA trials for (HR+/HER2-) Advanced Breast Cancer

Published: 8 Dec, 2018|Tags: Novartis, Reports, Results, Kisqali (ribociclib), Endocrine Therapy, P-III, MONALEESA trials, (HR+/HER2-), Advanced Breast Cancer

14. Bristol-Myers (BMS) Collaborates with Vedanta Biosciences to Develop Combination Therapy for Advanced or Metastatic Cancers

Published: 10 Dec, 2018|Tags: Bristol-Myers (BMS), Collaborates, Vedanta Biosciences, Develop, Combination, Therapy, Advanced or Metastatic Cancers, Opdivo, (nivolumab), VE800

15. AstraZeneca Reports Imfinzi (durvalumab) & tremelimumab Results in P-III EAGLE trial for Advanced Head and Neck Cancer

Published: 10 Dec, 2018|Tags: AstraZeneca, Reports, Imfinzi, (durvalumab), tremelimumab, Results, P-III, EAGLE trial, Advanced Head and Neck Cancer

16. Merck Licenses Cyclica’s In-Silico Artificial Intelligence (AI) based Ligand Express Platform 

      Published: 10 Dec, 2018|Tags: Merck, Licenses, Cyclica, In-Silico, Artificial Intelligence (AI), Ligand Express Platform 

17. Daiichi Reports Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in P-I study for HER2 Low Expressing Metastatic Breast Cancer

      Published: 8 Dec, 2018|Tags: Daiichi, Reports, Results, [Fam-] Trastuzumab Deruxtecan, (DS-8201), P-I study, HER2, Low Expressing Metastatic Breast Cancer